First to See the Light

Category: Uncategorized

ST Supports 6th Annual World Polio Day

GREENWICH, Conn., PRNewswire/ — Spencer Trask & Co., a privately held advanced technology development firm, joins UNICEF and the Bill & Melinda Gates Foundation as sponsor of World Polio Day on Oct. 24, 2018. This is the sixth year Rotary International is producing the event to raise awareness for the global eradication of polio. Rotary […]

Firm Funded by ST Acquired by Circle

Crowdfunding Firm Funded by Spencer Trask & Co. Acquired by Circle GREENWICH, Conn., PRNewswire/ — SeedInvest, the equity crowdfunding firm funded by Spencer Trask & Co., was acquired by global peer-to-peer payments technology company Circle Internet Financial Ltd. (Circle). Spencer Trask affiliates were major investors in the Series A round for SeedInvest. “The SeedInvest team […]

Trensant AI Acquired by Interos Solutions

GREENWICH, Conn./PRNewswire/ — Spencer Trask & Co., an advanced technology development firm, today announced that Interos Solutions, Inc. has acquired the patented Artificial Intelligence (AI) platform developed by its portfolio venture, Trensant, Inc. Interos provides supply chain risk assessment to major corporations and departments and agencies of the U.S. Federal government. Trensant AI reads, processes […]

ST and Affiliates Close Sale of ImThera

Spencer Trask & Co. and its Affiliated Investors Close the Sale of ImThera Medical, Inc. OLD GREENWICH, Conn./PRNewswire/ — Spencer Trask & Co., a privately held advanced technology development firm, is pleased to announce the sale of ImThera Medical, Inc. (“ImThera”), a privately owned company focused on neurostimulation for the treatment of obstructive sleep apnea […]

Chairman Gives Talk on Smartphone Origin

Spencer Trask & Co Chairman Kevin Kimberlin Gives Presentation on the Origin of First Pocket Sized Cell Phone OLD GREENWICH, Conn., PRNewswire/ — Spencer Trask & Co., a privately held advanced technology development firm, today released a presentation that its Chairman Kevin Kimberlin gave in conjunction with this year’s Mobile World Congress Americas event in […]

ST Chairman at Mobile World Congress

Spencer Trask - Our Legacy

OLD GREENWICH, CT (Sept. 11, 2017) – Spencer Trask & Co., a leading business and technology development firm, today announced its chairman Kevin Kimberlin was invited to participate in a panel discussion at Mobile World Congress Americas. Taking place at San Francisco’s Moscone Center (Moscone North, M2M Zone) on Sept. 12, 2017, the panel begins […]

DLF to Honor Spencer Trask & CO. Chairman

GREENWICH, Conn., PRNewswire/ — Spencer Trask & Co. an advanced technology development firm, today announced its Chairman Kevin Kimberlin, along with his wife Joni, will be presented with the “Lifetime in Service for Peace” award on Mon., June 5 by the David Lynch Foundation during a fundraising event held at The John F. Kennedy Center […]

ST Recognizes 100 Year Anniversary

GREENWICH, Conn., PRNewswire/ — Spencer Trask & Co., a privately held advanced technology company, is recognizing the 100 year anniversary of Albert Einstein’s publication of his paper on quantum theory of radiation with a contribution to the Institute for Advanced Study, where Einstein served as a professor from 1935-1955. Spencer Trask Chairman Kevin Kimberlin helped achieve […]

What’s your bright idea?

1 (800) 622 -7078

ideas@spencertraskco.com

Linkedin Twitter
Contact Us

The Immune Response Corporation

Revolution in Immunotherapy

DISCOVERY – Non-infectious viral vaccines.

INNOVATOR – In the history of medicine, few figures have had as profound an impact on human health and wellbeing as Dr. Jonas Salk. His polio vaccine breakthrough was the culmination of centuries of research, dating back to Louis Pasteur discovering inoculation. However, Salk’s method was different. He found a way to protect people from viruses without giving them the very disease the vaccine was designed to prevent.

Using this no-infection method, Salk worked with Kevin Kimberlin of Spencer Trask to develop cancer vaccines and an immunotherapeutic to slow or prevent AIDS. They patented and conducted preclinical studies on a cancer vaccine that demonstrated a startling 90% protection against lethal malignancies. 

IMPACT – A fusion of dendritic cells and the cancer antigen, their technology formed the basis for the first FDA-approved cell-based immunotherapy. Over 40,000 men with metastatic castrate-resistant prostate cancer have received the treatment, and it appears especially effective for African-American men who receive a 48% improved survival benefit compared to white men.

The team and facility making this immunotherapy also made clinical and commercial supplies of the first approved gene therapy, the CAT-T drug Kymriah.

The first approved cell-base immunotherapy and gene therapy prompted the FDA Commissioner to say, “New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses.”

The noninfectious vaccine approach developed by Jonas Salk eliminated polio from the developed countries, his flu vaccine mitigated the effects of influenza for the past 75 years, and finally, the cancer vaccine developed at his Immune Response Corporation led the way to gene, cell-based, and immune therapy innovations that will impact human health for generations. In summary, Salk released the last step in enabling the most important preventative medicine – non-infectious viral vaccination.